REMINDER: Boralex to hold Investor Day and present its 2030 Strategy on June 17, 2025
MONTREAL, June 16, 2025 (GLOBE NEWSWIRE) — Boralex inc. ('Boralex' or the 'Company') (TSX: BLX) announces that its 2030 Strategy will be presented at an Investor Day on June 17, 2025, from 10 a.m. to 12:30 p.m., in Toronto.
Financial analysts, investors and the media are invited to attend the conference in person in Toronto or via a live video webcast during which members of Boralex's senior management will present the various aspects of the 2030 Strategy and financial targets.
Date and time
Tuesday, June 17, 2025, from 10 a.m. to 12:30 p.m. (ET)
To attend the live conference
Webcast link:
https://meetings.lumiconnect.com/400-747-683-475
In person in Toronto (analysts, investors and media): please contact Dominique Hamelin (
dominique.hamelin@boralex.com
) to reserve your place.
Anyone interested in this conference are invited to attend the webcast, which will be broadcast live and available for replay on Boralex's website at
www.boralex.com
until July 17, 2026.
Media availability
Members of Boralex's Executive Committee will be available for media interviews on the afternoon of June 17, 2025, either by telephone or videoconference, to discuss the company's 2030 Strategy. For more information or to schedule an interview, please contact Camille Laventure, Senior Advisor, Public Affairs and Communications. Her contact details are provided at the end of this press release.
About Boralex
At Boralex, we have been providing affordable renewable energy accessible to everyone for over 30 years. As a leader in the Canadian market and France's largest independent producer of onshore wind power, we also have facilities in the United States and development projects in the United Kingdom. Over the past five years, our installed capacity has increased by more than 50% to 3.2 GW. We are developing a portfolio of projects in development and construction of more than 8 GW in wind, solar and storage projects, guided by our values and our corporate social responsibility (CSR) approach. Through profitable and sustainable growth, Boralex is actively participating in the fight against global warming. Thanks to our fearlessness, discipline, expertise and diversity, we continue to be an industry leader. Boralex's shares are listed on the Toronto Stock Exchange under the ticker symbol BLX.
For more information, visit
boralex.com
or
sedarplus.com
. Follow us on
Facebook
,
LinkedIn
and
Instagram
.
For more information
Source: Boralex inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
10 minutes ago
- Hamilton Spectator
Jane Silverstone Segal Increases Number of Shares of DAVIDsTEA Inc. Under Her Control
MONTREAL, June 20, 2025 (GLOBE NEWSWIRE) — Jane Silverstone Segal, Chair of the Board of Directors of DAVIDsTEA Inc. ('DAVIDsTEA') (TSXV: DTEA), announces that on June 20, 2025, she received shares of Rainy Day Investments Ltd. ('RDI') by way of bequest from her late husband Mr. Herschel Segal, as a result of which Jane Silverstone Segal has voting control of RDI. RDI owns 12,012,538 common shares of DAVIDsTEA, representing 44.51% of DAVIDsTEA's issued and outstanding common shares, which shares are now controlled by Jane Silverstone Segal. Immediately prior to the transfer of shares described above, Jane Silverstone Segal held 127,087 common shares of DAVIDsTEA, representing 0.47% of its 26,985,738 issued and outstanding common shares. Immediately after the transfer of shares described above, Mrs. Segal holds or exercises control, directly or indirectly, over 12,139,625 common shares, representing 44.99% of DAVIDsTEA's issued and outstanding common shares. As a result of the transfer of shares described above, Mrs. Segal's holdings of DAVIDsTEA's common shares increased to 44.99% from 0.47%. The late Mr. Herschel Segal also held 1,523 common shares of DAVIDsTEA directly, representing 0.006% of the issued and outstanding shares. The 1,523 shares will be transferred to Jane Silverstone Segal by way of bequest in due course, following which she will hold or exercise control, directly or indirectly, over 12,141,148 common shares, representing 44.99% of DAVIDsTEA's issued and outstanding common shares. In accordance with applicable securities laws, Mrs. Segal may, from time to time and at any time, acquire additional DAVIDsTEA shares and/or other equity, debt or other securities or instruments (collectively, 'Securities') of DAVIDsTEA in the open market or otherwise, and Mrs. Segal reserves the right to dispose of any or all of her Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the DAVIDsTEA and other relevant factors. A copy of an early warning report filed by Jane Silverstone Segal in connection with the transfer described above is available on SEDAR+ under DAVIDsTEA's profile. This news release is issued under the early warning provisions of Canadian securities legislation. To obtain a copy of the early warning report filed by Jane Silverstone Segal, please contact: Frank Zitella President, Chief Operating and Chief Financial Officer DAVIDsTEA Inc. 5775 Ferrier Street Mount Royal, Québec H4P 1N3 Telephone: 514-839-1580
Yahoo
17 minutes ago
- Yahoo
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275
Yahoo
32 minutes ago
- Yahoo
TFSA: 3 Canadian Stocks to Buy and Hold for a Lifetime
Written by Amy Legate-Wolfe at The Motley Fool Canada Building wealth doesn't have to be complicated. With a Tax-Free Savings Account (TFSA), Canadians can grow their money over time without worrying about taxes on gains or income. But the key is picking the right stocks, ones you can hold for decades. The best TFSA stocks aren't necessarily the most exciting. They're the ones that quietly deliver strong returns, pay dividends, and stay resilient in all kinds of markets. Three great examples today are CCL Industries (TSX:CCL.B), Manulife (TSX:MFC), and WSP Global (TSX:WSP). CCL is one of the world's largest producers of labels and packaging. While that might not sound thrilling, it's a business built for stability. CCL has over 200 production facilities around the world, serving clients in healthcare, food, consumer goods, and tech. In its most recent earnings report, CCL reported revenue of $1.9 billion, up 8.6% from the year before. Earnings per share (EPS) hit $1.18, and free cash flow swung back to positive after a brief dip last year. This shows CCL isn't just growing, it's generating real cash that can support future expansion and dividends. The dividend stock currently pays a dividend yield of 1.6%, and it has a history of raising that payout over time. Then there's Manulife, one of Canada's largest insurance and wealth management companies. It operates in Canada, the U.S., and across Asia, giving it a strong global footprint. In its most recent quarter, Manulife reported $1.8 billion in core earnings, a steady result despite some market headwinds. Core earnings per share rose to $0.99 from $0.91 the year before. Net income dropped, mainly due to changes in investment values, but the core business remained strong. Its Canadian division saw solid insurance growth and lower expenses, while Asia showed promise as demand for wealth products improved. Manulife's dividend yield sits around 4.2%, and it has a long track record of rewarding shareholders. Finally, WSP Global is a lesser-known gem that delivers engineering and infrastructure consulting services around the world. Whether it's public transit systems, bridges, or green buildings, WSP is helping design the world's future. In its latest quarter, WSP saw revenue climb 22.4% to $4.4 billion, with net earnings of $144 million or $1.10 per share. That's up from $126 million last year. The dividend stock also reported a backlog of $16.6 billion, meaning it has years of projects already lined up. WSP's dividend is modest at just 0.55%, but it has room to grow thanks to strong earnings and demand. What makes all three of these stocks ideal for a TFSA is their mix of income, growth, and staying power. None of them are highly speculative. Each one operates in industries that are essential, whether it's consumer packaging, financial services, or infrastructure development. Each also generates healthy free cash flow, which supports dividend payouts and long-term investments in the business. Investors could invest $5,000 across all three today and collect quarterly dividends, with the potential for steady capital growth. And because these dividend stocks are diversified in what they do and where they operate, you get some built-in protection from market swings. In fact, $5,000 across each would bring in annual dividends of $316.60! COMPANY RECENT PRICE NUMBER OF SHARES DIVIDEND TOTAL PAYOUT FREQUENCY INVESTMENT TOTAL CCL.B $78.11 64 $1.28 $81.92 Quarterly $4,999.04 MFC $42.18 118 $1.76 $207.68 Quarterly $4,977.24 WSP $272.26 18 $1.50 $27 Quarterly $4,900.68 A TFSA is one of the best tools Canadians have to build long-term wealth. The sooner you start filling it with solid, income-generating stocks like CCL, Manulife, and WSP, the more time you will give your investments to grow tax-free. You don't need to check the market every day. Just buy quality businesses, sit back, and let compounding do the rest. The post TFSA: 3 Canadian Stocks to Buy and Hold for a Lifetime appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool recommends CCL Industries and WSP Global. The Motley Fool has a disclosure policy. 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
